Daiwa Capital Markets Downgrades Takeda Pharmaceutical (NYSE:TAK) to Neutral

Daiwa Capital Markets lowered shares of Takeda Pharmaceutical (NYSE:TAK) from an outperform rating to a neutral rating in a research note published on Thursday morning, Briefing.com Automated Import reports.

Several other equities analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Takeda Pharmaceutical from a buy rating to a hold rating in a research report on Wednesday, August 7th. ValuEngine lowered shares of Takeda Pharmaceutical from a hold rating to a sell rating in a research report on Wednesday, May 15th.

Shares of TAK opened at $16.72 on Thursday. The company has a market capitalization of $26.34 billion, a price-to-earnings ratio of 32.78 and a beta of 0.69. The company’s 50 day simple moving average is $17.52. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.01 and a current ratio of 1.46. Takeda Pharmaceutical has a twelve month low of $15.50 and a twelve month high of $21.95.



A number of hedge funds have recently made changes to their positions in the business. HM Payson & Co. acquired a new stake in Takeda Pharmaceutical during the second quarter worth $80,000. Ladenburg Thalmann Financial Services Inc. boosted its stake in Takeda Pharmaceutical by 6.6% during the second quarter. Ladenburg Thalmann Financial Services Inc. now owns 40,712 shares of the company’s stock worth $716,000 after buying an additional 2,509 shares in the last quarter. Prestige Wealth Management Group LLC acquired a new stake in Takeda Pharmaceutical during the second quarter worth $25,000. Voloridge Investment Management LLC acquired a new stake in Takeda Pharmaceutical during the second quarter worth $385,000. Finally, Covenant Partners LLC boosted its stake in Takeda Pharmaceutical by 7.6% during the second quarter. Covenant Partners LLC now owns 63,483 shares of the company’s stock worth $1,124,000 after buying an additional 4,480 shares in the last quarter. Institutional investors own 11.31% of the company’s stock.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.

Further Reading: How to calculate the intrinsic value of a stock

Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.